Truist moved Edwards from Hold to Buy and raised its share target from $95 to $113. The more positive analyst view supports a favorable reading, though no company results or plans changed.
The report's only company-specific information is Truist's more favorable view. It gives no new sales, profit, or product details, so the positive reading rests on the analyst's opinion.
Follow Edwards Lifesciences Corporation (EW) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EW